Skip to main content

Table 2 B-cell phenotype distribution in PB and SF in AB+ and AB− RA and no-RA patients.

From: B-Cell Subsets in the Joint Compartments of Seropositive and Seronegative Rheumatoid Arthritis (RA) and No-RA Arthritides Express Memory Markers and ZAP70 and Characterize the Aggregate Pattern Irrespectively of the Autoantibody Status

B-cell subpopulation (flow cytometry)

RA patients, AB+, n = 14

RA patients, AB−, n = 13

P

No-RA patients, n = 13

P a

P b

PB

      

WBC count (n/μL)

8,428 ± 3,146

8,363 ± 2,876

0.87

7,061 ± 2,037

0.21

0.23

Lymphocytes (%)

32.7 ± 12.4

28.8 ± 12.8

0.51

27.8 ± 11.1

0.48

0.71

Lymphocytes (n/μL)

2,760 ± 1,160

2,082 ± 651

0.06

2,038 ± 1,002

0.13

0.71

CD19 (%)

7.8 ± 4.5

8.4 ± 5.2

0.83

7.9 ± 4.5

0.85

0.82

Bml (%)

31.3 ± 12.1

25.3 ± 15.4

0.25

17.3 ± 6.7

0.08

0.32

Bm2+Bm2′ (%)

28.1 ± 20.6

35.1 ± 19.3

0.57

48.4 ± 6.2

0.11

0.25

eBm5 (%)

11.2 ± 4.8

15.8 ± 8.8

0.48

15.7 ± 6.3

0.20

1.00

Bm5 (%)

24.7 ± 22.3

20.0 ± 16.7

0.89

16.1 ± 11.0

1.00

0.57

Ratio Bm2+Bm2′/

2.3 ± 3.1

1.4 ± 1.0

0.89

1.6 ± 0.6

0.75

0.89

eBm5+Bm5

      

IgD+/CD27− (%)

49.4 ± 24.6

49.7 ± 21.4

0.89

62.5 ± 6.0

0.75

0.39

IgD+/CD27+ (%)

11.5 ± 6.8

14.2 ± 14.2

0.67

5.7 ± 3.8

0.05

0.25

IgD−/CD27+ (%)

24.6 ± 15.4

23.2 ± 17.0

0.89

14.4 ± 6.7

0.26

0.39

IgD−/CD27− (%)

14.3 ± 8.8

12.9 ± 5.6

0.89

17.4 ± 9.8

0.63

0.74

CD19+/

8.2 ± 3.8

11.6 ± 9.9

0.67

8.0 ± 4.4

1.00

0.67

CD27+CD38+ (%)

      

CD19+/ZAP70+(%)

7.6 ± 6.9

6.6 ± 4.6

1.00

4.0 ± 2.8

0.46

0.25

SF

      

WBC count (n/μL)

14,480 ± 12,375

13,150 ± 13,085

0.67

14,920 ± 10,656

0.71

0.58

Lymphocytes (%)

26.4 ± 19.0

13.1 ± 9.1

0.07

19.4 ± 12.2

0.34

0.20

Lymphocytes (n/μL)

2,213 ± 1,609

1,092 ± 857

0.08

1,878 ± 1,278

0.58

0.14

CD19 (%)

2.2 ± 3.0

0.8 ± 0.5

0.14

0.6 ± 0.8

0.02

0.16

Bm1 (%)

25.7 ± 32.8

17.5 ± 11.1

0.67

12.2 ± 5.7

0.43

0.34

Bm2+Bm2′(%)

2.2 ± 0.8

5.0 ± 4.4

0.20

2.1 ± 1.0

0.93

0.15

eBm5 (%)

14.1 ± 11.2

14.8 ± 8.5

0.62

15.2 ± 12.3

0.62

0.75

Bm5 (%)

53.1 ± 28.6

60.4 ± 8.2

1.00

68.7 ± 14.6

0.35

0.34

Ratio Bm2+Bm2′/

0.03 ± 0.01

0.07 ± 0.06

0.14

0.03 ± 0.01

0.65

0.15

eBm5+Bm5

      

IgD+/CD27− (%)

19.7 ± 18.3

17.6 ± 6.8

0.78

11.0 ± 3.4

0.52

0.05

IgD+/CD27+ (%)

9.0 ± 15.2

7.8 ± 8.0

0.48

6.3 ± 4.5

0.52

0.87

IgD−/CD27+ (%)

53.7 ± 12.1

51.4 ± 17.3

1.00

60.9 ± 5.4

0.41

0.52

IgD−/CD27− (%)

30.7 ± 16.6

23.2 ± 11.8

0.15

21.8 ± 8.6

0.22

0.69

CD19+/

      

CD27+CD38+ (%)

7.6 ± 7.3

8.5 ± 7.1

0.89

10.0 ± 7.9

0.43

0.75

CD19+/ZAP70+(%)

28.5 ± 27.5

20.9 ± 12.6

0.96

22.2 ± 12.6

0.96

0.83

  1. Data are means ± SD. Kruskal-Wallis test: no significant differences between RA AB+, RA AB− and no-RA patients.
  2. aMann-Whitney test between RA AB+ and no-RA patients.
  3. bMann-Whitney test between RA AB− and no-RA patients.
Back to article page

Molecular Medicine

ISSN: 1528-3658